A Single Arm, Tolerability and Safety Phase IV Study of Fulvestrant(Faslodex® ) as 2nd Line and Later Therapy in Postmenopausal Women With Locally Advanced or Metastatic Breast Cancer

Clinical trial NCT02447328 · COMPLETED

Trial details

NCT number: NCT02447328
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 4
Study type: INTERVENTIONAL

Locally Advanced or Metastatic Breast Cancer

Start date: 2015-05-29
Primary completion: 2016-05-06
Enrollment: 83

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.